BB Biotech AG

Matchpoint Therapeutics has closed a $150 million Series B financing co-led by Nextech Invest and Norwest. New investors Invus, BB Biotech, T1D Fund, and BOLD Longevity Growth participated, alongside founding investors Access Biotechnology and Atlas Venture, lead Series A investor Sanofi Ventures, Digitalis Ventures, and all other existing investors. Proceeds will support progression of the lead asset MPT-062, an oral first-in-class T cell modulator, to clinical proof-of-concept, with clinical development to begin in 2027, and advancement of the company's broader pipeline, including an additional program funded by Novartis through their July 2025 agreement. Kanishka Pothula, Managing Partner at Nextech Invest, and Brian Matesic, Principal at Norwest, will join Matchpoint's Board of Directors in connection with the financing. Matchpoint is a privately held biotechnology company based in Watertown, Massachusetts, developing oral medicines for autoimmune and inflammatory diseases.